What is SIGA's market cap?

$226.33M, based on the Nov 4 close of $3.15.

Does SIGA Technologies pay a dividend?

Yes. The latest regular dividend was $0.6 per share (ex-date Apr 7), an annualised yield of 19.05%.

How much of SIGA is sold short?

3.6M shares, 8.8% of float, as of Oct 15, 2026.

What sector is SIGA in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · SIGAHealthcarePharmaceuticals

SIGA Technologies Inc. (SIGA)

$3.15+1.29%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$3.15▼ 61.30% in range

Nov 4, 2025Low $2.87 · High $8.43Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

SIGA Technologies closed at $3.15 on Nov 4, up 1.29%, 62.6% below its 52-week closing high. Volume of 313.9K shares was 0.64× its 20-day average (below normal).

Split-adjusted performance: -4.3% over one month, -33.0% over six months, -61.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $41M, down 49.5% from a year earlier, with a net margin of 30.4%.

Short interest was 3.6M shares at the Oct 15 settlement, down 1.0% from the prior report (8.8% of float, 6.4 days to cover).

Market cap$226.3M71.8M shares

Revenue · quarter$41.0M−49.5% YoY

Diluted EPS$0.17−65.3% YoY

P/E · TTM—P/S 4.2×

Net margin30.4%Gross 57.2%

Dividend yield19.05%$0.6 last paid

52-week range2.87 – 8.43−62.6% from high

Volume313.9K0.64× 20-day avg

Volatility · 60d43.0%Annualised

Short % of float8.8%6.4 days to cover

Net cash$117.6MCash $117.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −4.8%1M −4.3%3M +1.0%6M −33.0%YTD −48.4%1Y −61.6%3Y −36.9%5Y −56.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum41

Revenue growth23

Net margin90

Value (low P/E)—

Size50

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.6M−1.0% vs prior

Days to cover6.4Settled Oct 15

% of float8.8%

Short vol. 10d36.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
SIGASIGA Technologies	$3.15	+1.29%	−33.0%	−49.5%	30.4%	—	$226.3M
NATRNature's Sunshine Products	$12.84	+6.38%	−51.1%	+1.9%	3.0%	12.5	$225.9M	Compare
ADCTADC Therapeutics SA	$1.72	+10.97%	−55.4%	+2.2%	−86.1%	—	$219.6M	Compare
ELDNEledon Pharmaceuticals	$2.70	+3.05%	−28.9%	—	—	—	$219.4M	Compare
EVMNEvommune	$6.04	+1.68%	−74.7%	—	—	—	$219.2M	Compare
VNDAVanda Pharmaceuticals	$3.88	+3.47%	−47.8%	+24.1%	−32.3%	—	$234.6M	Compare
CAMPCAMP4 Therapeutics	$3.74	−2.35%	−7.9%	+18.8%	−1884.8%	—	$234.7M	Compare
KROSKeros Therapeutics	$10.83	0.00%	−8.1%	−100.0%	—	—	$214.7M	Compare
GLSIGreenwich LifeSciences	$16.35	+2.70%	−29.1%	—	—	—	$240.0M	Compare

News about SIGA Technologies

All news →

SIGA (SIGA) Q1 2026 Earnings Call TranscriptThe Motley Fool · May 7, 2026▲ Positive SIGA Declares Special Cash Dividend of $0.60 Per ShareBenzinga · Mar 26, 2026▲ Positive ACTG Announces Publication of STOMP Results in the New England Journal of MedicineGlobeNewswire Inc. · Feb 25, 2026▼ Negative

Quick answers

What does SIGA Technologies do?: SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S.
What is SIGA's market cap?: $226.33M, based on the Nov 4 close of $3.15.
Does SIGA Technologies pay a dividend?: Yes. The latest regular dividend was $0.6 per share (ex-date Apr 7), an annualised yield of 19.05%.
How much of SIGA is sold short?: 3.6M shares, 8.8% of float, as of Oct 15, 2026.
What sector is SIGA in?: Healthcare, in the Pharmaceuticals industry.

About SIGA Technologies

SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.

HQ: New York, NY49 employeesListed Sep 9, 1997siga.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology